Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Auto Ventshade Hood Protector (Honda Civic Hybrid 2003)
Popular Articles

Higher Prevalence Of Early Menarche Among Survivors Of Childhood Sexual Abuse
African-American women who were younger at menarche, or the onset of their menstrual periods, were more likely to report a history of childhood sexual abuse, according to a new study led by a researcher at Boston University"s Slone Epidemiology Center. The results suggest that a history of sexual abuse may increase the risk of early menarche (i.e., onset of menstrual periods before age 12 years).

Buy lamisil to treat nail fungus.
PROSTVAC(TM) Data Presented At The ASCO Meeting Demonstrates The Potential For Significant Increases In Life Expectancy In Late-Stage Prostate Cancer
Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study.
News of the day
NACDS, NCPA Endorse Rep. Mike Ross' Medication Therapy Management Legislation
Today, the National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) announced their support for H.R. 3108, the Medication Therapy Management Benefits Act of 2009, sponsored by Rep. Mike Ross (D-AR). The bill was introduced on Friday June 26, 2009, and was immediately referred to the Committee on Energy and Commerce and Committee on Ways and Means, two House committees with jurisdiction over comprehensive healthcare reform legislation.
Public Health

New Study Shows Nexium 40 Mg And 20 Mg Reduced Gastric And Duodenal Ulcers By 80 - 85% In Patients Taking Low-Dose Aspirin For CV Protection

Esomeprazole significantly reduced the occurrence of gastric and duodenal ulcers and upper gastrointestinal (GI) symptoms in patients taking low-dose aspirin for risk reduction of adverse cardiovascular (CV) events[i], such as myocardial infarction (MI) and ischaemic stroke, according to new data presented today at the Digestive Diseases Week annual meeting (DDW, 30thMay - 4th June, Chicago). GI side effects related to the upper GI tract, which include dyspeptic symptoms with or without development of a gastric or duodenal ulcer, are a common reason for patients discontinuing their low-dose aspirin therapy for prevention of cardiovascular events.[ii],[iii] The data from the OBERON trial, a double-blind, randomised, prospective analysis of 2426 patients, revealed that esomeprazole 20mg and 40mg reduced the cumulative proportion of patients with peptic ulcers as well as the proportion of patients with gastric or duodenal ulcers when analysed separately after 26 weeks of treatment by 80-85% .i During the OBERON study period, follow-up endoscopy revealed gastric or duodenal ulcers in 7.4% of patients in the placebo group compared with 1.1% and 1.5 % of those in the esomeprazole 20 mg and 40 mg groups respectively (pAbout NEXIUM® (esomeprazole magnesium) In the US Nexium 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for treatment of heartburn and other symptoms associated with GERD. Nexium 40 mg and 20 mg daily are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). Nexium® is approved in Europe for indication in adults for treating frequent, persistent heartburn and other symptoms associated with acid reflux (GERD) and for the healing and maintenance of healing of erosive esophagitis. Nexium® is also approved in the short-term treatment of GERD in children aged 1-17 years. Nexium® is also indicated in the EU for healing of gastric ulcers associated with NSAID therapy and prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk. About Digestive Diseases Week DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 30 - June 4, 2009, at the McCormick Place, Chicago, IL. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org. References [i] Scheiman, J. Prevention of Low-Dose Acetylsalicylic Acid-Associated Gastric/Duodenal Ulcers with Esomeprazole 20mg and 40mg Once Daily in Patients at Increased Risk of Ulcer Development: a Randomised Controlled Trial (OBERON). Data to be presented at Digestive Disease Week 2009. Oral presentation 412. [ii] Yeomans et al. Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. Am J Gastroenterol 2008;103:2465-2473 [iii] Dyspeptic symptoms and sleep disturbance; a report from a large observational study in low dose acetylsalicylic acid users. Data to be presented at Digestive Disease Week 2009. Poster T1050 [iv] A Randomised, Blinded, Trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE), The Lancet, Vol 348, 1996, 1329 - 1339 [v] Thiefin et al. Prevalence and clinical impact of upper gastrointestinal symptoms in patients treated with low dose aspirin. Abstract 1924 [vi] Canadian retrospective cohort study: One year compliance with low-dose ASA therapy was 74.4% (Simpson et al 2003) [vii] Biondi-Zoccai et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. European Heart Journal (2006) 27, 2667-2674 AstraZeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009